▲ +7.78% Upside Potential
This price target is based on 15 analysts offering 12 month price targets for Exact Sciences in the last 3 months. The average price target is $145.31, with a high forecast of $226.00 and a low forecast of $70.00. The average price target represents a 7.78% upside from the last price of $134.82.
The current consensus among 15 investment analysts is to buy stock in Exact Sciences. This Buy consensus rating has held steady for over two years.
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype MAP, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.